Multiple Myeloma and Infections: Characterizing the Risks
Despite newer agents being available to patients with multiple myeloma, the rate of infections in this patient population has remained relatively unchanged.
Multiple Myeloma
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Myeloma Trial Aims to Use Genetic Profile for Treatment Optimization
To improve options for patients with refractory disease, researchers seek to bolster data behind genetic profiling as a way to guide the selection of treatment.
Carfilzomib Dosing and Scheduling in Newly Diagnosed Multiple Myeloma
Twice-weekly administration of carfilzomib requires patients to receive carfilzomib infusions on 2 consecutive days each week.
Comparing Efficacy and Safety of Auto-HCT in Older and Younger Patients With Multiple Myeloma
The efficacy and safety of autologous hematopoietic stem cell transplantation (auto-HCT) performed during the era of novel agents was comparable between elderly and younger patients with multiple myeloma, according to results of a retrospective study published in Bone Marrow Transplantation. Uncertainty remains regarding the risks and benefits of auto-HCT in elderly patients (≥ 65 years).…
clonoSEQ and MRD Testing in Multiple Myeloma and ALL
Medicare coverage has been announced for Adaptive Biotechnologies’ clonoSEQ® next-generation sequencing assay for the detection of minimal residual disease (MRD) after treatment for multiple myeloma or B-cell acute lymphoblastic leukemia (ALL) — a key step toward its use for patient care in cancer clinics in the United States.1,2The FDA announced regulatory approval for the assay…
Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cancer Topics, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Endocrine Cancer, Gastrointestinal Cancers, General Oncology, Gynecologic Cancer, Head and Neck Cancer, Hematologic Cancers, Lung Cancer, Lymphoma, Multiple Myeloma, Pancreatic Cancer, Pediatric Cancer, Prostate Cancer, Renal Cell Carcinoma, Sarcoma, Skin Cancer, Urologic Cancers
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%…
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.
Opinion: Understanding the FDA’s Take on Cannabidiol
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
“People have shown that the variant-identification quality of WGS is superior to WES,” said Dr Gerstein.
Next post in General Oncology
